Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: University of Alabama at Birmingham, University of Maryland, Baltimore, Dana-Farber Cancer Institute, City Of Hope National Medical Center, City of Hope, Sarah Cannon, Colorado Blood Cancer Institute, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Bristol-Myers Squibb (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310103242